[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100615705":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":47,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":10,"enrollmentInfo":60,"targetDuration":63,"studyType":64,"phases":10,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":29,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"University of Coimbra","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"patients with HFrEF and HFpEF",null,"patients with HFrEF (non-ischemic dilated cardiomyopathy) and HFpEF (hypertrophic cardiomyopathy)",[13],"Diagnostic Test: 68Ga-FAPI PET\u002FCT",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","68Ga-FAPI PET\u002FCT","Positron emission tomography\u002Fcomputed tomography (68Ga-FAPI PET\u002FCT)",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"João Borges Rosa, MD","CONTACT","+351239400400","joaopedroborgesrosa@gmail.com",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Faculdade de Medicina da Universidade de Coimbra","RECRUITING","Coimbra","Coimbra District","3000-548","Portugal","PT",{"type":36,"coordinates":37},"Point",[38,39],-8.41996,40.20686,{"lat":39,"lon":38},[42],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","João Pedro Borges Rosa","MD, Cardiologist, PhD Student",[48],{"name":49,"class":6},"Unidade Local de Saúde de Coimbra, EPE","100615705","ga-fapi-petct-for-cardiac-fibrosis-in-heart-failure-100615705",false,"NCT07296081","⁶⁸Ga-FAPI PET\u002FCT for Cardiac Fibrosis in Heart Failure","Myocardial Fibrosis in Heart Failure: A Pilot Study With 68Ga-FAPI PET\u002FCT","MY-FAPI","Inclusion Criteria:\n\n* ≥ 18 years old;\n* Signs and symptoms of heart failure (HF);\n* \\[Preserved left ventricular ejection fraction (LVEF) (≥50%) and Evidence of structural\u002Ffunctional abnormality consistent with diastolic dysfunction\u002Fincreased ventricular filling pressures, including elevated natriuretic peptides and Imaging diagnosis of hypertrophic cardiomyopathy and Genetic diagnosis of hypertrophic cardiomyopathy due to sarcomeric gene mutation\\] OR \\[Reduced LVEF (≤40%) and Imaging diagnosis of dilated cardiomyopathy: left ventricular end-diastolic diameter \\>58 mm in men and \\>52 mm in women, and left ventricular volume ≥75 mL\u002Fm² in men and ≥62 mL\u002Fm² in women, not explained solely by loading conditions\\]\n* Recent transthoracic echocardiogram (\\\u003C 3 months);\n* Recent cardiac magnetic resonance imaging (\\\u003C 3 months).\n* Normal coronary angiogram or computed tomography coronary angiography within 6 months of enrolment\n\nExclusion Criteria:\n\n* Inability to provide informed consent;\n* Inability to tolerate the supine position;\n* Hemodynamic instability;\n* Claustrophobia;\n* Chronic kidney disease with glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73m²;\n* Pregnant or breastfeeding women;\n* Malignant neoplasms within the past 5 years;\n* Significant primary valvular disease;\n* Significant atherosclerotic coronary artery disease;\n* Grade 2 or 3 arterial hypertension;\n* Presence of an implanted cardiac electrical device;\n* Recent hospitalization for heart failure (\\\u003C30 days).","ALL","18 Years",{"count":61,"type":62},30,"ESTIMATED","2 Years","OBSERVATIONAL","Heart failure (HF) is a clinical syndrome with increasing incidence and prevalence, associated with high morbidity, mortality, and economic impact, despite therapeutic advances.\n\nMyocardial fibrosis is a common feature across different pathophysiological processes and plays a key role in HF development, with growing research interest specifically in non-ischemic dilated cardiomyopathy (HFrEF phenotype) and hypertrophic cardiomyopathy (HFpEF phenotype). Given its potential reversibility with certain drugs, fibrosis is an attractive therapeutic target, requiring non-invasive methods to monitor fibrogenesis and treatment efficacy.\n\nCardiac magnetic resonance imaging (CMR) is the gold standard for detecting fibrosis but cannot distinguish between active and inactive fibrosis or detect early stages, limitations that may be addressed by gallium-68-labeled fibroblast activation protein inhibitor positron emission tomography\u002Fcomputed tomography (68Ga-FAPI PET\u002FCT).\n\nThis single-center, prospective, observational pilot study aims primarily to assess myocardial fibrosis in patients with HFrEF (non-ischemic dilated cardiomyopathy) and a subtype of HFpEF (hypertrophic cardiomyopathy) using 68Ga-FAPI PET\u002FCT compared to CMR.\n\nSecondary objectives include developing 68Ga-FAPI uptake assessment methodologies for future anti-fibrotic therapy studies and correlating fibrosis with serum cardiac biomarkers and cardiovascular events.",[67,68],"Myocardial Fibrosis","Heart Failure",[70,71,72,73,74],"Fibroblast activation protein inhibitors","Gallium-68","Heart failure","Myocardial fibrosis","Positron emission tomography","2025-12-21",{"date":77,"type":78},"2025-12-29","ACTUAL",{"date":80,"type":78},"2025-11-17",{"date":82,"type":62},"2028-12-31",{"name":5,"class":6},1]